Literature DB >> 23247726

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

John C Riches1, Jeffrey K Davies, Fabienne McClanahan, Rewas Fatah, Sameena Iqbal, Samir Agrawal, Alan G Ramsay, John G Gribben.   

Abstract

T-cell exhaustion, originally described in chronic viral infections, was recently reported in solid and hematologic cancers. It is not defined whether exhaustion contributes to T-cell dysfunction observed in chronic lymphocytic leukemia (CLL). We investigated the phenotype and function of T cells from CLL patients and age-matched controls. CD8+ and CD4+ T cells from CLL patients had increased expression of exhaustion markers CD244, CD160, and PD1, with expansion of a PD1+BLIMP1HI subset. These molecules were most highly expressed in the expanded population of effector T cells in CLL. CLL CD8+ T cells showed functional defects in proliferation and cytotoxicity, with the cytolytic defect caused by impaired granzyme packaging into vesicles and nonpolarized degranulation. In contrast to virally induced exhaustion, CLL T cells showed increased production of interferon-γ and TNFα and increased expression of TBET, and normal IL2 production. These defects were not restricted to expanded populations of cytomegalovirus (CMV)–specific cells, although CMV seropositivity modulated the distribution of lymphocyte subsets, the functional defects were present irrespective of CMV serostatus. Therefore, although CLL CD8+ T cells exhibit features of T-cell exhaustion, they retain the ability to produce cytokines. These findings also exclude CMV as the sole cause of T-cell defects in CLL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23247726      PMCID: PMC3587324          DOI: 10.1182/blood-2012-09-457531

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  A novel transcription factor, T-bet, directs Th1 lineage commitment.

Authors:  S J Szabo; S T Kim; G L Costa; X Zhang; C G Fathman; L H Glimcher
Journal:  Cell       Date:  2000-03-17       Impact factor: 41.582

2.  Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals.

Authors:  Naeem Khan; Naseer Shariff; Mark Cobbold; Rachel Bruton; Jenni A Ainsworth; Alan J Sinclair; Laxman Nayak; Paul A H Moss
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

3.  T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.

Authors:  Angela M Krackhardt; Sabine Harig; Mathias Witzens; Ryan Broderick; Patrick Barrett; John G Gribben
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

4.  The silent war against CMV in CLL.

Authors:  Arne N Akbar
Journal:  Blood       Date:  2010-10-21       Impact factor: 22.113

5.  Human regulatory T cells induce T-lymphocyte senescence.

Authors:  Jian Ye; Xingxu Huang; Eddy C Hsueh; Qunyuan Zhang; Chunling Ma; Yanping Zhang; Mark A Varvares; Daniel F Hoft; Guangyong Peng
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

6.  Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia.

Authors:  Wendelina J M Mackus; Florine N J Frakking; Annette Grummels; Laila E Gamadia; Godelieve J De Bree; Dorte Hamann; Rene A W Van Lier; Marinus H J Van Oers
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

7.  Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.

Authors:  J Piñón Hofbauer; C Heyder; U Denk; T Kocher; C Holler; D Trapin; D Asslaber; I Tinhofer; R Greil; A Egle
Journal:  Leukemia       Date:  2011-05-24       Impact factor: 11.528

8.  Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.

Authors:  Claudia Nunes; Ryan Wong; Malcolm Mason; Chris Fegan; Stephen Man; Chris Pepper
Journal:  Clin Cancer Res       Date:  2011-12-21       Impact factor: 12.531

9.  The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire.

Authors:  Batoul Pourgheysari; Rachel Bruton; Helen Parry; Lucinda Billingham; Chris Fegan; Jim Murray; Paul Moss
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

10.  Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes.

Authors:  A Anumanthan; A Bensussan; L Boumsell; A D Christ; R S Blumberg; S D Voss; A T Patel; M J Robertson; L M Nadler; G J Freeman
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

View more
  204 in total

1.  CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.

Authors:  Isabelle Magalhaes; Ingrid Kalland; James N Kochenderfer; Anders Österborg; Michael Uhlin; Jonas Mattsson
Journal:  J Immunother       Date:  2018 Feb/Mar       Impact factor: 4.456

2.  Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

Authors:  Mark B Geyer; Isabelle Rivière; Brigitte Sénéchal; Xiuyan Wang; Yongzeng Wang; Terence J Purdon; Meier Hsu; Sean M Devlin; M Lia Palomba; Elizabeth Halton; Yvette Bernal; Dayenne G van Leeuwen; Michel Sadelain; Jae H Park; Renier J Brentjens
Journal:  JCI Insight       Date:  2019-04-02

3.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

4.  PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.

Authors:  Bola S Hanna; Philipp M Roessner; Annika Scheffold; Billy M C Jebaraj; Yasmin Demerdash; Selcen Öztürk; Peter Lichter; Stephan Stilgenbauer; Martina Seiffert
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

5.  mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

Authors:  Troels Holz Borch; Lotte Engell-Noerregaard; Trine Zeeberg Iversen; Eva Ellebaek; Özcan Met; Morten Hansen; Mads Hald Andersen; Per Thor Straten; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2016-07-08       Impact factor: 8.110

6.  CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.

Authors:  Hadas Lewinsky; Avital F Barak; Victoria Huber; Matthias P Kramer; Lihi Radomir; Lital Sever; Irit Orr; Vita Mirkin; Nili Dezorella; Mika Shapiro; Yosef Cohen; Lev Shvidel; Martina Seiffert; Yair Herishanu; Shirly Becker-Herman; Idit Shachar
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 7.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

8.  Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.

Authors:  H Parry; G McIlroy; R Bruton; M Ali; C Stephens; S Damery; A Otter; T McSkeane; H Rolfe; S Faustini; N Wall; P Hillmen; G Pratt; S Paneesha; J Zuo; A Richter; P Moss
Journal:  Blood Cancer J       Date:  2021-07-30       Impact factor: 11.037

9.  Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells.

Authors:  Didem Ozkazanc; Digdem Yoyen-Ermis; Ece Tavukcuoglu; Yahya Buyukasik; Gunes Esendagli
Journal:  Immunology       Date:  2016-09-29       Impact factor: 7.397

10.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.